Colitis: all 1,059 studies

Page 7 of 11. Open to participants first (124), then studies with results posted, then the rest; newest registration first within each.

• To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative ColitisCompletedNCT03412682Phase 3
• Monocultivar Coratina Extra Virgin Olive Oil in UC PatientsStatus unknownNCT03408847Not applicable
• Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIECCompletedNCT03404557
• Real-world Data Regarding Treatment of Ulcerative Colitis Patients With GolimumabStatus unknownNCT03394586
• A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real LifeTerminatedNCT03378388
• PediCRaFT: Pediatric Crohn's Disease Fecal Transplant TrialCompletedNCT03378167Phase 1
• Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female SubjectsCompletedNCT03327558Phase 1
• Prevalence of Graves Disease in Patients With Ulcerative ColitisStatus unknownNCT03324334
• Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.WithdrawnNCT03309865Early Phase 1
• Personalized Research on Diet in Ulcerative Colitis and Crohn's DiseaseCompletedNCT03301311Not applicable
• The PRognostic Effect of Environmental Factors in Crohn's and ColitisCompletedNCT03282903
• Faecal Microbiota Transplantation in Patients With Microscopic ColitisCompletedNCT03275467Not applicable
• Fecal Microbiota Transplantation in Ulcerative ColitisStatus unknownNCT03273465Phase 2
• Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate ColitisCompletedNCT03268213Early Phase 1
• Primary Cecal Pathologies Presenting as Acute AbdomenCompletedNCT03262025
• Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel DiseaseStatus unknownNCT03239704Not applicable
• An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative ColitisWithdrawnNCT03237260Phase 4
• Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative ColitisCompletedNCT03235752Phase 2
• The Promotion Plan of Moxibustion on Ulcerate ColitisCompletedNCT03232528Not applicable
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• Stricture Definition and Treatment (STRIDENT) Observational Study.TerminatedNCT03218202
• Infliximab Accelerated Induction in Moderate to Severe Pediatric UCTerminatedNCT03209232Not applicable
• Granulocyte-monocyte Apheresis in Ulcerative ColitisCompletedNCT03189888Not applicable
• Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose OptimizationCompletedNCT03182166Phase 2
• Evaluation of Early Mucosal Healing During Clinical Remission in Pediatric Ulcerative ColitisCompletedNCT03179865
• Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-upTerminatedNCT03172195Not applicable
• Detection of Helicobacter Pylori in Ulcerative Colitis PatientsStatus unknownNCT03172000Not applicable
• The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative ColitisStatus unknownNCT03151850
• Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative ColitisStatus unknownNCT03151525Phase 4
• Fecal Calprotectin Collection ProtocolCompletedNCT03143517
• Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative ColitisCompletedNCT03142113
• Curcumin for Prevention of Relapse in Patients With Ulcerative ColitisTerminatedNCT03122613Not applicable
• Restoration of the Microbiome Through Superdonor SelectionStatus unknownNCT03110289Not applicable
• Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative ColitisStatus unknownNCT03110198Phase 4
• Faecal Bacteriotherapy for Ulcerative ColitisCompletedNCT03104036Phase 2
• TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)CompletedNCT03103412Phase 1
• Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative ColitisStatus unknownNCT03101800Phase 3
• Dysplasia in Inflammatory Chronic Idiopathic Colitis Long-standingStatus unknownNCT03096717
• Counseling to Optimize Adherence in Expectant Mothers With Inflammatory Bowel DiseaseStatus unknownNCT03091309Not applicable
• Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging MarketsCompletedNCT03090139
• Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy SubjectsCompletedNCT03071081Phase 1
• Identification/Characterization of Changes in Microscopic ColitisStatus unknownNCT03063957
• The Effect of Diet on Disease Activity and Symptoms in Patients With Ulcerative ColitisCompletedNCT03053713Not applicable
• A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy VolunteersCompletedNCT03038711Phase 1
• Study of E6007 in Japanese Patients With Moderate Active Ulcerative ColitisCompletedNCT03018054Phase 2
• Fecal Microbiota Transplantation for Ulcerative ColitisStatus unknownNCT03016780Phase 1/2
• Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat ColitisWithdrawnNCT03014284
• Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative ColitisCompletedNCT03006809Phase 1
• Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel DiseaseCompletedNCT03000101Not applicable
• Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral TubingStatus unknownNCT02998112Phase 4
• GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )CompletedNCT02994836Phase 4
• A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)CompletedNCT02986724
• A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative ColitisCompletedNCT02985593Phase 1
• EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota TransplantWithdrawnNCT02968511Not applicable
• Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative ColitisWithdrawnNCT02962245Phase 4
• Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU)CompletedNCT02943538Not applicable
• Prevention of Readmissions at IBD Centres of ExcellenceStatus unknownNCT02931799Not applicable
• The Effects of Moxibustion on Ulcerative ColitisCompletedNCT02931162Not applicable
• Microbiota-targeted Diet for Pediatric UCCompletedNCT02922881Not applicable
• Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative ColitisStatus unknownNCT02922374Phase 1/2
• The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative ColitisCompletedNCT02914717
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's DiseaseWithdrawnNCT02913508Phase 2
• Mercaptopurine Therapy in Ulcerative ColitisStatus unknownNCT02910245Phase 3
• Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site CohortCompletedNCT02897271
• Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative ColitisCompletedNCT02888379Phase 2
• Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)TerminatedNCT02878083Not applicable
• Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With InfliximabCompletedNCT02868398
• Ulcerative Colitis Relapse Prevention by PrebioticsCompletedNCT02865707Not applicable
• Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative ColitisTerminatedNCT02864264Phase 1
• Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel DiseasesCompletedNCT02862132Not applicable
• In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative ColitisStatus unknownNCT02852850
• A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)TerminatedNCT02849951Phase 3
• CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)CompletedNCT02825914Not applicable
• RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding ColitisCompletedNCT02822352Not applicable
• TD-1473 for Active Ulcerative Colitis (UC)CompletedNCT02818686Phase 1
• Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative ColitisCompletedNCT02818543Phase 1
• Anti-TNF Therapy for Refractory Colitis in Hospitalized ChildrenCompletedNCT02799615
• Linked Color Imaging vs. White Light for Colorectal Dysplasia in Ulcerative ColitisStatus unknownNCT02772406Not applicable
• Optimising Infliximab Induction Therapy for Acute Severe Ulcerative ColitisCompletedNCT02770040Phase 4
• Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative ColitisStatus unknownNCT02768974Phase 2
• Intestinal Microbiome and Chronic Inflammatory Bowel DiseaseWithdrawnNCT02768038
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyWithdrawnNCT02760615Phase 4
• A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)CompletedNCT02749630Phase 1
• Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)CompletedNCT02748590Not applicable
• Localized Therapeutics for the Treatment of Gastrointestinal Disorders IICompletedNCT02745678Phase 1
• Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life ConditionsCompletedNCT02738125
• Fecal Transplantation Using a Diet for Donor and Recipient in Refractory ColitisTerminatedNCT02734589Not applicable
• Predicting Clinical Response to Golimumab With Mucosal Barrier DysfunctionWithdrawnNCT02729233Not applicable
• Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative ColitisStatus unknownNCT02721823Not applicable
• The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative ColitisActive, not recruitingNCT02721719
• Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic ColonoscopyCompletedNCT02709213
• Risk Factors for Microscopic ColitisCompletedNCT02699333
• Mission is Remission®: How Can a Disease Self-management Website Change Care?TerminatedNCT02694042Not applicable
• Phenotyping IBS: Perceptions and Modulations of Visceral SensationsCompletedNCT02693730
• Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in ColitisStatus unknownNCT02687724Phase 4
• Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative ColitisCompletedNCT02684734
• Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative ColitisStatus unknownNCT02683759Phase 3
• Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative ColitisStatus unknownNCT02683733Phase 3
• Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative ColitisStatus unknownNCT02676817
• Entyvio (Vedolizumab) Long Term Safety StudyCompletedNCT02674308

← Colitis overview